Dr Christopher Flowers: Liso-Cel Approval for Mantle Cell Lymphoma Changes the Treatment Strategy
June 7th 2024The latest approval of lisocabtagene maraleucel (liso-cel) in mantle cell lymphoma provides another treatment option and continues the tremendous advances in treatment for patients, said Christopher Flowers, MD, of MD Anderson Cancer Center.
Read More
Patients With T1D and HCPs Talk Social Media and Self-Management
June 7th 2024Synthesizing 11 qualitative studies, authors present a nuanced picture of how patients with type 1 diabetes (T1D), and the health care professionals (HCPs) who treat them, feel about using social media platforms as a self-management tool—and where improvements can be made.
Read More
New Data May Help Guide Optimization of Pediatric MG Treatment Duration
June 6th 2024Researchers say their findings will help inform treatment protocols for this patient population, as questions remain about optimal duration of these treatments following first-line treatment with pyridostigmine.
Read More
US tuberculosis (TB) programs have helped to identify those with TB and latent TB infection and ensure they completed treatment; FDA advisers instructed that the COVID-19 vaccine Americans will receive in the fall should target the JN.1 strain; lawmakers are divided over the CMS nursing home staffing mandate.
Read More
Inotuzumab Ozogamicin Plus Dose-Adjusted EPOCH: Promise in R/R B-ALL
June 5th 2024Phase 1 trial results indicate that combining inotuzumab ozogamicin with dose-adjusted EPOCH chemotherapy could offer a safe, well-tolerated, and effective treatment option for patients with relapsed or refractory CD22+ B-cell acute lymphoblastic leukemia or lymphoma (R/R B-ALL).
Read More
Antibody Drug Conjugates Show Promise in Biomarker, Prognostic Outcomes in Oncology Care
June 5th 2024Posters presented at ASCO 2024 found positive responses in the prediction of tumor types and prognostic outcomes in patients with advanced solid tumors and HR+/HER2-negative (HER2–) metastatic breast cancer.
Read More
Prophylaxis With Recombinant ADAMTS13 Demonstrates Superiority vs Standard Therapy in Congenital TTP
June 5th 2024The multinational, open-label, controlled, randomized, crossover, phase 3 TAK-755 (NCT03393975) trial demonstrated superior efficacy and safety of recombinant ADAMTS13 as prophylaxis in patients with congenital thrombotic thrombocytopenic purpura (cTTP) compared with standard therapy.
Read More
FDA advisers have voted against the use of MDMA as a post-traumatic stress disorder (PTSD) treatment; House members have expressed support for the 340B drug discount program but disagreed on whether it needs tighter regulation; a federal judge sided with SCAN Health Plan over CMS about incorrect 2024 Star Rating calculations.
Read More
Equity in Motion at CMS Health Equity: Dr Aletha Maybank Shares AMA Advances for Justice
June 5th 2024Chief Health Equity Officer and Senior Vice President Aletha Maybank, MD, MPH, of the American Medical Association (AMA), delivered a powerful plenary session at the CMS Health Equity conference exploring the changes sparked by pivotal moments within the last 5 years.
Read More
Same Hypertension, Different Levels of Portal Engagement, Disparities Research Shows
June 4th 2024When patients are treated in primary care for high blood pressure, sociodemographic factors sway the rates at which they access patient portals, investigators found. This could influence their hypertension outcomes.
Read More
Gathering Data on Circadian Rhythms, Sleep in Adolescents Poses Challenges in Lab and Home Testing
June 4th 2024The session held at SLEEP 2024 focused on the challenges of collecting data on sleep and circadian rhythms in adolescents, as well as the difference between home and lab measurements.
Read More
Mental Health Care Dominates Telehealth Visits, Study Finds
June 3rd 2024An analysis drawing on data from the 2021 Medical Expenditure Panel Survey (MEPS) highlights that a significant portion of telehealth visits were for mental health services despite the overall telehealth utilization being relatively low.
Read More